 Kristina Brooks
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 24 | 2025 | 754 | 5.680 |
Why?
| | HIV Infections | 28 | 2025 | 2721 | 4.430 |
Why?
| | Adenine | 10 | 2025 | 256 | 3.040 |
Why?
| | Pregnancy Complications, Infectious | 9 | 2025 | 367 | 2.750 |
Why?
| | Tenofovir | 12 | 2025 | 231 | 2.390 |
Why?
| | Emtricitabine | 11 | 2025 | 168 | 2.010 |
Why?
| | Alanine | 9 | 2025 | 142 | 1.800 |
Why?
| | Pre-Exposure Prophylaxis | 7 | 2022 | 203 | 1.660 |
Why?
| | Antiviral Agents | 6 | 2025 | 712 | 1.440 |
Why?
| | Phosphorous Acids | 2 | 2019 | 13 | 1.280 |
Why?
| | Sofosbuvir | 4 | 2025 | 58 | 1.210 |
Why?
| | Organophosphates | 5 | 2025 | 120 | 1.200 |
Why?
| | Heterocyclic Compounds, 3-Ring | 4 | 2025 | 31 | 1.000 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 63 | 0.890 |
Why?
| | Darunavir | 1 | 2023 | 18 | 0.870 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 9 | 0.840 |
Why?
| | Benzimidazoles | 3 | 2025 | 162 | 0.800 |
Why?
| | Fluorenes | 2 | 2020 | 40 | 0.800 |
Why?
| | Isoniazid | 2 | 2023 | 63 | 0.790 |
Why?
| | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 2 | 2018 | 17 | 0.750 |
Why?
| | Blood Platelets | 1 | 2025 | 380 | 0.750 |
Why?
| | Drug Monitoring | 3 | 2022 | 215 | 0.710 |
Why?
| | Cobicistat | 4 | 2023 | 5 | 0.680 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 767 | 0.670 |
Why?
| | Neutrophils | 1 | 2025 | 1207 | 0.640 |
Why?
| | Hepatitis C | 1 | 2022 | 238 | 0.640 |
Why?
| | Rifampin | 2 | 2025 | 83 | 0.630 |
Why?
| | Biomarkers, Pharmacological | 1 | 2018 | 26 | 0.600 |
Why?
| | Drug Interactions | 6 | 2019 | 393 | 0.600 |
Why?
| | Antibiotics, Antitubercular | 1 | 2018 | 37 | 0.600 |
Why?
| | Pregnancy | 13 | 2025 | 6392 | 0.590 |
Why?
| | Medication Adherence | 6 | 2024 | 556 | 0.590 |
Why?
| | HIV Integrase Inhibitors | 1 | 2019 | 69 | 0.580 |
Why?
| | Busulfan | 1 | 2017 | 15 | 0.580 |
Why?
| | Transplantation Conditioning | 1 | 2017 | 166 | 0.520 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 66 | 0.500 |
Why?
| | Dried Blood Spot Testing | 4 | 2024 | 94 | 0.500 |
Why?
| | Complementary Therapies | 1 | 2016 | 87 | 0.490 |
Why?
| | Tandem Mass Spectrometry | 3 | 2025 | 522 | 0.480 |
Why?
| | Infectious Disease Transmission, Vertical | 4 | 2025 | 170 | 0.480 |
Why?
| | Female | 32 | 2025 | 68494 | 0.480 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 2 | 2025 | 19 | 0.470 |
Why?
| | Humans | 43 | 2025 | 129144 | 0.460 |
Why?
| | Leukocytes, Mononuclear | 4 | 2025 | 545 | 0.450 |
Why?
| | Prospective Studies | 8 | 2025 | 7117 | 0.430 |
Why?
| | Chromatography, Liquid | 4 | 2025 | 423 | 0.420 |
Why?
| | Adult | 19 | 2025 | 35469 | 0.420 |
Why?
| | Bronchitis | 1 | 2013 | 43 | 0.410 |
Why?
| | Polyphosphates | 3 | 2022 | 36 | 0.400 |
Why?
| | Postpartum Period | 4 | 2025 | 332 | 0.400 |
Why?
| | Rare Diseases | 1 | 2013 | 98 | 0.390 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 572 | 0.390 |
Why?
| | Cross-Over Studies | 4 | 2023 | 520 | 0.390 |
Why?
| | Cytokines | 2 | 2018 | 2012 | 0.360 |
Why?
| | Fontan Procedure | 1 | 2013 | 173 | 0.360 |
Why?
| | Protease Inhibitors | 2 | 2022 | 106 | 0.350 |
Why?
| | Hepatitis C, Chronic | 2 | 2025 | 153 | 0.350 |
Why?
| | Drug Combinations | 4 | 2025 | 330 | 0.330 |
Why?
| | Transgender Persons | 2 | 2022 | 172 | 0.320 |
Why?
| | Pyridones | 3 | 2025 | 158 | 0.310 |
Why?
| | Blood Chemical Analysis | 2 | 2019 | 96 | 0.310 |
Why?
| | Young Adult | 12 | 2025 | 12385 | 0.310 |
Why?
| | Janus Kinase 1 | 2 | 2018 | 24 | 0.290 |
Why?
| | Janus Kinase 2 | 2 | 2018 | 32 | 0.290 |
Why?
| | Piperazines | 3 | 2025 | 340 | 0.290 |
Why?
| | Oxazines | 2 | 2018 | 27 | 0.290 |
Why?
| | Azetidines | 2 | 2018 | 40 | 0.290 |
Why?
| | Janus Kinase Inhibitors | 2 | 2018 | 25 | 0.290 |
Why?
| | Male | 18 | 2025 | 63456 | 0.280 |
Why?
| | Dabigatran | 2 | 2017 | 21 | 0.280 |
Why?
| | Healthy Volunteers | 5 | 2018 | 200 | 0.270 |
Why?
| | Lactation | 3 | 2023 | 169 | 0.270 |
Why?
| | Levofloxacin | 1 | 2025 | 25 | 0.240 |
Why?
| | Carbamates | 1 | 2025 | 46 | 0.230 |
Why?
| | Tuberculosis, Multidrug-Resistant | 1 | 2025 | 57 | 0.230 |
Why?
| | Infant | 6 | 2025 | 8975 | 0.230 |
Why?
| | Hepacivirus | 2 | 2025 | 235 | 0.220 |
Why?
| | Sulfonamides | 2 | 2018 | 495 | 0.220 |
Why?
| | Macaca nemestrina | 1 | 2023 | 29 | 0.210 |
Why?
| | Dideoxynucleosides | 1 | 2023 | 20 | 0.210 |
Why?
| | Tablets | 1 | 2023 | 35 | 0.210 |
Why?
| | Lamivudine | 1 | 2023 | 61 | 0.210 |
Why?
| | Antitubercular Agents | 1 | 2025 | 200 | 0.210 |
Why?
| | Middle Aged | 9 | 2025 | 31050 | 0.200 |
Why?
| | Prenatal Care | 1 | 2024 | 274 | 0.190 |
Why?
| | Breast Feeding | 2 | 2023 | 423 | 0.190 |
Why?
| | Cell Phone | 1 | 2022 | 70 | 0.190 |
Why?
| | Adolescent | 9 | 2022 | 20297 | 0.190 |
Why?
| | Pregnant Women | 1 | 2022 | 114 | 0.190 |
Why?
| | HIV | 1 | 2023 | 227 | 0.190 |
Why?
| | Pregnancy Outcome | 2 | 2024 | 389 | 0.190 |
Why?
| | Viral Load | 1 | 2023 | 448 | 0.180 |
Why?
| | Ritonavir | 2 | 2020 | 73 | 0.180 |
Why?
| | Administration, Oral | 3 | 2017 | 785 | 0.180 |
Why?
| | Oligonucleotides, Antisense | 2 | 2017 | 113 | 0.170 |
Why?
| | Mobile Applications | 1 | 2022 | 160 | 0.170 |
Why?
| | Antithrombins | 2 | 2017 | 58 | 0.160 |
Why?
| | Fetus | 1 | 2023 | 770 | 0.150 |
Why?
| | Hereditary Autoinflammatory Diseases | 1 | 2018 | 6 | 0.150 |
Why?
| | Ethanol | 1 | 2023 | 589 | 0.150 |
Why?
| | Drug Dosage Calculations | 1 | 2017 | 22 | 0.140 |
Why?
| | COP9 Signalosome Complex | 1 | 2017 | 5 | 0.140 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2017 | 10 | 0.140 |
Why?
| | Hair Cells, Auditory, Inner | 1 | 2017 | 14 | 0.140 |
Why?
| | Jejunostomy | 1 | 2017 | 12 | 0.140 |
Why?
| | Morpholinos | 1 | 2017 | 31 | 0.140 |
Why?
| | Latent Tuberculosis | 1 | 2018 | 67 | 0.140 |
Why?
| | Administration, Intravenous | 1 | 2017 | 141 | 0.140 |
Why?
| | Inflammation | 2 | 2018 | 2735 | 0.130 |
Why?
| | Interferons | 1 | 2018 | 191 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2016 | 18 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1363 | 0.130 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 400 | 0.130 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2016 | 6 | 0.130 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2016 | 151 | 0.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2016 | 35 | 0.120 |
Why?
| | Gadolinium | 1 | 2016 | 78 | 0.120 |
Why?
| | Enteral Nutrition | 1 | 2017 | 188 | 0.120 |
Why?
| | Receptors, LDL | 1 | 2015 | 47 | 0.120 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 123 | 0.120 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 166 | 0.120 |
Why?
| | Blood Coagulation | 1 | 2016 | 238 | 0.120 |
Why?
| | Models, Biological | 2 | 2022 | 1722 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1040 | 0.110 |
Why?
| | Doxorubicin | 1 | 2016 | 328 | 0.110 |
Why?
| | Telemedicine | 1 | 2022 | 789 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 426 | 0.110 |
Why?
| | Tissue Plasminogen Activator | 1 | 2015 | 222 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2025 | 10192 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1943 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 314 | 0.100 |
Why?
| | Intestinal Mucosa | 1 | 2017 | 589 | 0.100 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2022 | 83 | 0.100 |
Why?
| | Child | 5 | 2022 | 20768 | 0.090 |
Why?
| | Benchmarking | 2 | 2024 | 176 | 0.090 |
Why?
| | Influenza, Human | 1 | 2017 | 601 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3077 | 0.090 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 484 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1276 | 0.080 |
Why?
| | Compassionate Use Trials | 2 | 2018 | 7 | 0.070 |
Why?
| | Infant, Newborn | 3 | 2025 | 5736 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1496 | 0.070 |
Why?
| | Thrombin Time | 2 | 2017 | 11 | 0.070 |
Why?
| | Purines | 2 | 2018 | 172 | 0.070 |
Why?
| | Benzopyrans | 1 | 2025 | 25 | 0.060 |
Why?
| | Holistic Health | 1 | 2024 | 15 | 0.060 |
Why?
| | Pregnancy Trimester, Third | 1 | 2025 | 109 | 0.060 |
Why?
| | Pyrazoles | 2 | 2018 | 404 | 0.060 |
Why?
| | Amides | 1 | 2025 | 91 | 0.060 |
Why?
| | Benzamides | 1 | 2025 | 203 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 3386 | 0.050 |
Why?
| | Animals | 4 | 2023 | 35286 | 0.050 |
Why?
| | Brain | 1 | 2016 | 2668 | 0.050 |
Why?
| | Glycerophospholipids | 1 | 2023 | 34 | 0.050 |
Why?
| | Fetal Blood | 1 | 2025 | 317 | 0.050 |
Why?
| | Anti-Retroviral Agents | 1 | 2024 | 231 | 0.050 |
Why?
| | Lung | 1 | 2015 | 3927 | 0.050 |
Why?
| | Diphosphates | 1 | 2021 | 17 | 0.050 |
Why?
| | Aged | 2 | 2018 | 21997 | 0.050 |
Why?
| | Hormones | 1 | 2022 | 140 | 0.050 |
Why?
| | Pyrimidines | 1 | 2025 | 458 | 0.050 |
Why?
| | Drug Approval | 1 | 2020 | 87 | 0.040 |
Why?
| | Lopinavir | 1 | 2020 | 30 | 0.040 |
Why?
| | Estradiol | 1 | 2022 | 493 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 372 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2018 | 30 | 0.040 |
Why?
| | Capsules | 1 | 2018 | 40 | 0.040 |
Why?
| | Developing Countries | 1 | 2020 | 284 | 0.040 |
Why?
| | Nanomedicine | 1 | 2018 | 32 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 97 | 0.040 |
Why?
| | Acoustic Maculae | 1 | 2017 | 1 | 0.040 |
Why?
| | Oocysts | 1 | 2017 | 5 | 0.040 |
Why?
| | Saccule and Utricle | 1 | 2017 | 6 | 0.040 |
Why?
| | Viral Matrix Proteins | 1 | 2017 | 29 | 0.040 |
Why?
| | Proteinuria | 1 | 2017 | 91 | 0.030 |
Why?
| | Placebos | 1 | 2017 | 201 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 117 | 0.030 |
Why?
| | Embryo, Nonmammalian | 1 | 2017 | 166 | 0.030 |
Why?
| | Area Under Curve | 1 | 2017 | 304 | 0.030 |
Why?
| | Patient Selection | 1 | 2020 | 660 | 0.030 |
Why?
| | Influenza A virus | 1 | 2017 | 100 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 399 | 0.030 |
Why?
| | Headache | 1 | 2017 | 151 | 0.030 |
Why?
| | Hand-Foot Syndrome | 1 | 2016 | 2 | 0.030 |
Why?
| | Tubulin | 1 | 2017 | 137 | 0.030 |
Why?
| | Axons | 1 | 2017 | 191 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1003 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2015 | 17 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 77 | 0.030 |
Why?
| | Carboplatin | 1 | 2016 | 139 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 122 | 0.030 |
Why?
| | Injections, Spinal | 1 | 2015 | 104 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 405 | 0.030 |
Why?
| | Actins | 1 | 2017 | 411 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2020 | 493 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2015 | 160 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1982 | 0.030 |
Why?
| | Intestines | 1 | 2017 | 347 | 0.030 |
Why?
| | Endocytosis | 1 | 2015 | 162 | 0.030 |
Why?
| | Epithelium | 1 | 2015 | 311 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 711 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2015 | 1085 | 0.030 |
Why?
| | Child, Preschool | 2 | 2018 | 10456 | 0.030 |
Why?
| | Body Weight | 1 | 2017 | 939 | 0.030 |
Why?
| | Zebrafish | 1 | 2017 | 458 | 0.030 |
Why?
| | Contrast Media | 1 | 2016 | 393 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1613 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 1874 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 644 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3372 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 3963 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 712 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 587 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2635 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3140 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2272 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 5408 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3071 | 0.020 |
Why?
| | Liver | 1 | 2015 | 1839 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2511 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 5438 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 14450 | 0.010 |
Why?
| | United States | 1 | 2016 | 13825 | 0.010 |
Why?
| | Mice | 1 | 2015 | 16905 | 0.010 |
Why?
|
|
Brooks's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|